Hims & Hers Health, Inc.

Semaglutide — the active ingredient in Ozempic and Wegovy — was placed on the FDA drug shortage list due to surging demand. Under FDA rules, compounding pharmacies are permitted to produce copies of drugs on the shortage list, and Hims & Hers took full advantage. By 2025, the company was selling a monthly GLP-1 injection kit at roughly $100-200 per month, compared to $1,000-1,300 for branded Ozempic. That price gap drove massive subscriber acquisition from patients who could not afford or could not get insurance coverage for the branded versions.

The regulatory risk is the central thesis debate for HIMS bulls and bears. When Novo Nordisk and Eli Lilly resolved supply issues for branded GLP-1 drugs, the FDA removed semaglutide from the shortage list — which legally required compounding pharmacies to stop producing it. Each FDA shortage-list update becomes a potential HIMS binary event, moving the stock 20-40% in a single session depending on the outcome.

HIMS is a high-volatility, event-driven stock. The average intraday range on a catalyst day can exceed 25%, making it one of the most actively day-traded healthcare names. The key is to identify which catalysts matter: FDA shortage-list updates and earnings releases are the highest-impact events, while smaller news around telehealth regulations or insurance coverage decisions create secondary moves.

The mean-reversion setup in HIMS is historically useful for traders with defined risk. After sharp regulatory selloffs, the stock has repeatedly found support around the base business valuation — the underlying telehealth platform has millions of subscribers paying recurring monthly fees, which creates a floor that is independent of the GLP-1 outcome. Buying oversold HIMS after a regulatory catalyst selloff with a clearly defined stop below recent lows has been a repeatable setup for experienced traders.